Retatrutide vs Tirzepatide: Which Triple Agonist Leads Metabolic Research?

Both retatrutide and tirzepatide represent significant advances over first-generation GLP-1 agonists like semaglutide, but they operate through different receptor combinations:

• Tirzepatide (Mounjaro / Zepbound, Eli Lilly): GLP-1 receptor + GIP receptor, dual agonist
• Retatrutide (LY3437943, Eli Lilly): GLP-1 receptor + GIP receptor + glucagon receptor, triple agonist

The addition of glucagon receptor agonism in retatrutide is the critical distinction. Glucagon receptor activation increases energy expenditure through hepatic glucose output modulation and thermogenesis, mechanisms not directly targeted by tirzepatide.

While no direct head-to-head clinical trial has yet compared retatrutide and tirzepatide, published Phase 2/3 data allows indicative comparison:

• Tirzepatide (SURMOUNT-1, 72 weeks, 15mg dose): mean body weight reduction ~22.5%
• Retatrutide (Phase 2, 48 weeks, 12mg dose): mean body weight reduction ~24.2%

The retatrutide result is notable because it was achieved in fewer weeks (48 vs 72) and the trajectory at 48 weeks had not yet plateaued in most participants, suggesting potential for greater reduction over a longer timeline. Phase 3 TRIUMPH trial data is expected to clarify this further.

Beyond weight, retatrutide's glucagon activity also showed reductions in liver fat content (relevant to NAFLD research) that exceeded tirzepatide's effects in available data, likely attributable to glucagon receptor-mediated hepatic fat oxidation.

GLP-1 receptor agonism (shared by both):

• Slows gastric emptying → prolonged satiety signalling
• Central appetite suppression via hypothalamic GLP-1 receptor activation
• Glucose-dependent insulin secretion

GIP receptor agonism (shared by both):

• Potentiates insulin secretion in a glucose-dependent manner
• Evidence of central appetite modulation via GIP receptors in the hypothalamus
• May improve GLP-1 tolerability (GIP agonism appears to reduce GLP-1-associated nausea)

Glucagon receptor agonism (retatrutide only):

• Increases hepatic glucose output, counteracted by concurrent GLP-1/GIP-mediated insulin release
• Stimulates thermogenesis via increased energy expenditure in adipose tissue
• Drives hepatic fat oxidation, potentially beneficial in fatty liver research models
• May increase basal metabolic rate independent of food intake reduction

The choice between retatrutide and tirzepatide in a research context depends on the specific pathways under investigation:

• Pure appetite and satiety signalling research: either compound is appropriate; tirzepatide has more published human data to reference
• Energy expenditure and thermogenesis research: retatrutide's glucagon component makes it the more relevant compound
• Fatty liver / hepatic fat metabolism: retatrutide's glucagon-mediated hepatic effects make it a stronger candidate for NAFLD/NASH research models
• Glucose metabolism and insulin dynamics: both compounds have effects, though the glucagon component in retatrutide adds complexity to insulin/glucagon ratio studies
• Weight reduction magnitude: current data favours retatrutide, though Phase 3 confirmation is pending

Both retatrutide and tirzepatide are available as research-grade compounds from Australian suppliers. OzPeps stocks research-grade retatrutide with fast AU shipping and discreet packaging.

View Retatrutide stock and pricing →

All compounds referenced in this article are sold by OzPeps strictly for in-vitro laboratory research purposes. Neither retatrutide nor tirzepatide (as supplied by research vendors) are TGA-approved therapeutic goods. Not for human or animal consumption.